Nifedipine is one of calcium channel blockers that commonly used clinically
to treat hypertension and angina in Egyptian patients. A sustained-release
(SR) formulation of nifedipine is available in the Egyptian community and
administered twice daily. This study aimed to to compare the
pharmacokinetics and safety profiles of a 20 mg SR and IR (immediate
release) formulation of nifedipine after single-dose administration in
healthy Egyptian subjects. Randomized, crossed open-label two- way clinical
trial, in 16 healthy adult volunteers, of 24.75±5.20 years, with BMI
23.26±1.756 were assessed. Blood samples were collected at
predefined times for 48 h and analyzed for Nifedipine plasma
concentrations using validated reversed phase liquid chromatography method
with ultraviolet detection. Pharmacokinetics was determined using non-
compartmental model pharmacokinetics and analyzed using one-way ANOVA
(P≤0.05). Following a single oral administration, SR formulation had
a lower Cmax, compared to IR formulation (54.46±17.75 ,
107.45±29.85 ng/mL, respectively), and
Tmax was significantly longer (2.97 vs. 1.13 h) for
the SR and IR formulation, respectively. There was no significant difference
between the SR and the IR formulations for AUC0–last and
AUC0-∞ (326.7±98.28 vs.
309.27±105.53 ng·h·mL−1
and 380.9 ± 105.24 vs.
334.36±108.1 ng·h·mL−1,
respectively). SR formulation of nifedipine showed similar pharmacokinetics
to the IR Formulation (F%=1.049), but it additionally allows
a less frequent administration. Therefore, The nifedipine SR and IR
formulations were well tolerated and displayed comparable safety
profiles.